AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03595592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
Study NCT03595592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
Study NCT03595592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
Study NCT03595592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
Study NCT03595592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Adriamycin will be delivered i.v. on day 1 every 3 weeks in arm ACy followed by HPCT for the first 3 cycles
Study NCT03595592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab for the first 3 cycles
Study NCT03595592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
Study NCT03595592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Breast cancer surgery (breast and axilla) either conservative or radical not later than 4 weeks from the last dose of neoadjuvant therapy in all study arms
Study NCT03595592 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Breast cancer surgery (breast and axilla) either conservative or radical not later than 4 weeks from the last dose of neoadjuvant therapy in all study arms
Study NCT01055262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heatwrap 1
Description: 8 hours continuous topically-applied heat
Study NCT03854396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasterone
Description: Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.
Study NCT03854396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks.
Study NCT03051581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/ CT
Description: 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
Study NCT04556136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standing Phototherapy Kiosk
Description: Benesol is a freestanding booth designed to deliver a small amount of targeted UVB with an interactive user interface and cloud-based software that enables patient self-care. The treatment delivery mechanism uses a metal halide lamp with a series of filters and a lens to optimize full-body exposure to the narrow spectrum (293 - 303nm) of UVB light most efficient at producing vitamin D3. The device uses software to identify patients, establish individual skin types and determine dosage. The system has been designed to manage exposure time and frequency and deliver 60% of a skin-type-adjusted Minimal Erythemal Dose (MED). The expected result for users is a rise in blood levels of 25(OH)D via the endogenous pathway.
Study NCT04556136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D3 Oral supplement
Description: Each subject assigned to the comparison group was instructed to take one vitamin D3 pill, dispensed by the research pharmacist, each day with a meal for 70 days. Subjects were instructed not to take any additional vitamin D supplementation during the study period. This dosing frequency is consistent with the RDA recommendation. Subjects were instructed to bring their pill bottle with them when returning for their follow up appointment.
Study NCT01793363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheotomy
Study NCT03933397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Specific Protocol
Description: Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home for pain and what was needed during their past hospital and emergency department visits to treat pain. Medicines will include opioids, either morphine or hydromorphone. A member of the outpatient SCD provider team will review the patient's medical record to determine: 1) the patient's maximum home opioid dose, and 2) previous ED analgesic medication(s) and doses that have been effective and safe in the past. The patient's regular hematologist/sickle cell team will write the treatment plans. Medications will be given every 20-30 minutes for up to 6 hours.
Study NCT03933397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-based Protocol
Description: Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight. Medicines will include opioids, either morphine or hydromorphone. Plans will be written by the patients regular hematologist/sickle cell team.
Study NCT03933397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 4 mg for participants weighing \<50 kgs, 6mg for participants weighing 50-69.9 kgs, 8mg for participants weighing 70 - 89.9 kgs and 10mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
Study NCT03933397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 1 mg for participants weighing \<60 kgs, 1.5 mg for participants weighing 60 - 89.9 kgs, and 2 mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
Study NCT01684904 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation
Study NCT03732079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound to measure the IVC diameter. The IVC diameter will be measured in the inspirium and the expirium, and the collapsibility index will be recorded.
Study NCT02576236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple concomitant therapy treatment
Description: Quadruple concomitant therapy treatment:~high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days
Study NCT02576236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triple therapy guided by the result of the molecular resistance test
Description: Triple therapy guided by the result of the molecular resistance test:~* If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.~* If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days.
Study NCT02728882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted CAR-T cells
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
Study NCT04331054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2: Usual practice + SYMBICORT RAPIHALER
Description: 2 puffs bid during 30 days by inhalation
Study NCT04331054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1: Usual practice
Description: Usual practice
Study NCT03681886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmoni Modular Intraocular Lens
Description: Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag.
Study NCT03681886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optic Exchange
Description: Removal of one optic and replacement with another for the purpose of improving refractive outcomes
Study NCT04780490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: liberal fluid management
Description: 10 ml/ kg/ hr Ringer's lactate solution
Study NCT04780490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: restrictive fluid management
Description: 2 ml/ kg/ hr Ringer's lactate solution with 2 mcg / kg / hr norepinephrine infusion
Study NCT01196533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive peripheral blood monitoring
Description: non invasive monitoring
Study NCT01289821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.
Study NCT01289821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: On day 1 and day 15 of each cycle, participants will receive 85 mg/m\^2 oxaliplatin as a 2 hour i.v. infusion.
Study NCT01289821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid) as a 2 hour i.v. infusion.
Study NCT01289821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU (mFOLFOX6)
Description: Participants will receive a 400 mg/m\^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m\^2 5 FU 46 hour i.v. infusion.
Study NCT00197808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: menjugate
Description: men C conjugate vaccine
Study NCT00197808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Men C conjugate vaccine
Description: men C conjugate vaccine
Study NCT00197808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Men C conjugate
Description: men C conjugate vaccine
Study NCT00197808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Men C Conjugate
Description: men C conjugate vaccine
Study NCT01009034 — intervention group
Intervention type: OTHER
Intervention: Measuring semen samples
Description: Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of maraviroc in semen, the variability in the penetration of maraviroc into the seminal compartment over the raltegravir dosing period.
Study NCT05421962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol.
Study NCT03521414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index (BIS) monitoring
Description: When the patients were taken to the operation table, they were monitored with the BIS. we used sevoflurane drug
Study NCT03521414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: we used sevoflurane drug at inoperative
Study NCT04549519 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention / Compare the difference in batting mechanics and bat-swing velocity in baseball players with good and poor lumbopelvic control
Study NCT00978835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored telephone-based case management
Description: Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
Study NCT00978835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse Education
Description: Didactic, non-interactive education by a nurse on general health topics. Calls are made every two months.
Study NCT00905684 — intervention group
Intervention type: DRUG
Intervention: EE30/DRSP (Yasmin, BAY86-5131)
Description: Patients under regular daily life treatment receiving Yasmin according to local drug information
Study NCT00905684 — intervention group
Intervention type: DRUG
Intervention: Any other OC
Description: Patients under regular daily life treatment receiving any other OC according to local drug information
Study NCT04130503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP
Description: Positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA).
Study NCT04130503 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HLE
Description: All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.
Study NCT04130503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HLE
Description: All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.
Study NCT04130503 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HLE
Description: All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.
Study NCT01009554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium Oxylate Mouthwash
Description: Rinse with 10 mL for 60 seconds, twice daily after brushing in usual manner with a sodium fluoride dentifrice
Study NCT01009554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride Dentifrice
Description: Brush in usual manner, twice daily, with a sodium fluoride dentifrice
Study NCT00800943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath-1H)
Description: Campath is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg,10mg,and 30mg, administered subcutaneously (SC) (if tolerated). When escalation to 30 mg dose is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 8 weeks
Study NCT01172405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen plus caffeine
Description: One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
Study NCT01172405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: One or two tablets of ibuprofen 400 mg when presenting headache.
Study NCT03594851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Description: The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score, and takes 5-10 minutes to complete. Developed by researchers at the University of Pittsburgh, the PSQI is intended to be a standardized sleep questionnaire for clinicians and researchers to use with ease and is used for multiple populations. The questionnaire has been used in many settings, including research and clinical activities, and has been used in the diagnosis of sleep disorders. Clinical studies have found the PSQI to be reliable and valid in the assessment of sleep problems to some degree, but more so with self-reported sleep problems and depression-related symptoms than actigraphic measures.
Study NCT03594851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep diary
Description: A sleep diary is a record of a patient's sleep patterns and habits that can be extremely useful in helping doctors make a diagnosis of a sleep disorder and better determine if a sleep study should be prescribed.
Study NCT03594851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Katz Index of Independence in Activities of Daily Living
Description: Katz Activities of Daily Living is a validated tool to assess functional status as a measurement of the elder's ability to perform activities of daily living independently. Elders are scored yes/no for independence in each of six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less implies severe functional impairment.
Study NCT03594851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lawton Instrumental Activities of Daily Living
Description: Lawton's Instrumental Activities of Daily Living (IADL) scale was developed to assess more complex activities (termed instrumental activities of daily living) necessary for functioning in community settings (e.g., shopping, cooking, managing finances). The capacity to handle these complex functions normally is lost before basic activities of daily living which are measured by Activities of Daily Living scales. Therefore, assessing Instrumental Activities of Daily Living may identify incipient decline in older adults who are otherwise capable and healthy.The Lawton Instrumental Activities of Daily Living scale takes approximately 10 to 15 minutes to administer. It contains 8 items that are rated with a summary score from 0 (low functioning) to 8 (high functioning). This scale can be administered through an interview or by a written questionnaire. The patient or a caregiver who is familiar with the patient can provide the answers.
Study NCT03594851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric Inventory (Cummings)
Description: Neuropsychiatric Inventory is submitted to the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.~The Neuropsychiatric Inventory (NPI) was developed by Cummings et al. (1994) to assess dementia-related behavioral symptoms which they felt other measures did not sufficiently address. The NPI originally examined 10 sub-domains of behavioral functioning: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor activity. Two more sub-domains have been added since its development: night-time behavioral disturbances and appetite and eating abnormalities (Cummings, 1997). This wide variety of domains means that, unlike other dementia measures, the NPI is able to screen for multiple types of dementia, not just Alzheimer's Disease.
Study NCT03594851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini Zarit Caregiver Burden Scale, for the caregiver
Description: Mini Zarit Caregiver Burden Scale, for the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.
Study NCT03594851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini Mental state examination
Description: It is an 11-question tool to evaluate cognitive functions. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment. The Mini Mental state examination takes only 5-10 minutes to administer and is therefore practical to use repeatedly and routinely.~The MMSE has been validated and extensively used in both clinical practice and research, since its creation in 1975
Study NCT03594851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cornell Scale for Depression in Dementia
Description: The Cornell scale For Depression in Dementia is a scoring system specifically developed to assess signs and symptoms of major depression in patients with dementia. The 19 parameters measured are clustered into five groups: mood-related signs, behavioural disturbances, physical signs, cyclic functions and ideational disturbances. The Cornell scale For Depression in Dementia has been shown to be sensitive, reliable and valid for assessing depression in patients with Alzheimer's disease.
Study NCT03594851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life in Alzheimer's Disease
Description: The Quality of Life in Alzheimer's Disease is a brief, 13-item measure designed specifically to obtain a rating of the patient's Quality of Life from both the patient and the caregiver. It was developed for individuals with dementia, based on patient, caregiver, and expert input, to maximize construct validity, and to ensure that the measure focuses on quality of life domains thought to be important in cognitively impaired older adults. It uses simple and straightforward language and responses \& includes assessments of the individual's relationships with friends and family, concerns about finances, physical condition, mood, and an overall assessment of life quality
Study NCT01813851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise training in addition to nutritional support